Knowledge Bank — Gene Profiles
The Genes
Schwannomatosis is not one disease caused by one mutation. It is a family of conditions sharing a biology — Schwann cells that lose their growth controls — with different genetic causes, different associated risks, and different clinical pictures.
SWN patients need more than an NF specialist — they need a specialist in their subtype.
NF2-SWN and non-NF2 schwannomatosis share a tumor type — both produce schwannomas — but they diverge in almost every clinical detail that follows: what genes are involved, what other tumors appear, what symptoms dominate, what surveillance protocols apply, and what treatments are being studied. A specialist trained primarily in NF2-SWN brings expertise in bilateral vestibular schwannomas, hearing preservation, and merlin biology. That expertise does not automatically transfer to SMARCB1-, LZTR1-, or unknown-gene schwannomatosis, where the defining features are chronic pain, spinal tumors, and in many cases, a negative gene panel.
This is not a criticism of NF clinics. It is a structural fact about how the field developed. The 2022 international consensus that unified all schwannomatosis subtypes under a single umbrella is recent — clinical training, institutional experience, and trial access have not all kept pace. A clinic that primarily treats NF2-SWN may have seen very few SMARCB1 or LZTR1 patients. When choosing a specialist, patients should ask specifically about experience with their subtype — not just schwannomatosis generally.
Source: Plotkin SR et al., Genetics in Medicine, 2022; Evans DG et al., ERN GENTURIS Clinical Practice Guidelines, 2022; GeneReviews: LZTR1- and SMARCB1-Related Schwannomatosis (updated Dec 2025).
SWI/SNF Related BAF Chromatin Remodeling Complex Subunit B1
A subunit of SWI/SNF protein complexes that regulate gene activity by controlling how tightly DNA is packaged around proteins (chromatin remodeling). This mechanism governs gene expression during development, DNA repair, replication, cell growth, division, and differentiation. Acts as a tumor suppressor.
- Multiple schwannomas on peripheral and spinal nerves
- Lumbar spine most commonly affected
- Meningiomas (SMARCB1-specific — NOT seen in LZTR1 cases)
- Chronic pain (most common presenting symptom)
- Numbness and weakness
- Tingling sensations
- Bilateral vestibular schwannomas are an EXCLUSION criterion — their presence indicates NF2-SWN, not SMARCB1-related SWN
- Malignant peripheral nerve sheath tumor risk
- Typical onset ages 20–40
SMARCB1 has three distinct clinical syndromes depending on variant type and location: (1) SWN-SMARCB1 (schwannomas ± meningiomas, reduced penetrance), (2) Rhabdoid Tumor Predisposition Syndrome (aggressive pediatric cancers, high penetrance), and (3) Coffin-Siris syndrome (developmental disorder, no increased cancer risk). These are different conditions caused by different variant types in the same gene. MedlinePlus does not capture this nuance clearly. The Order uses SWN-SMARCB1 exclusively for the schwannomatosis phenotype.
Profile last updated 2026-08-19
Leucine Zipper Like Post Translational Regulator 1
Found in the Golgi apparatus — the cellular structure responsible for modifying and packaging newly produced proteins. LZTR1 may help stabilize the Golgi and interacts with the CUL3 ubiquitin ligase complex involved in marking proteins for degradation. Acts as a tumor suppressor by regulating cell growth and division.
- Multiple schwannomas on peripheral and spinal nerves
- Lumbar spine most commonly affected
- Chronic pain (most common presenting symptom)
- Numbness and weakness
- Tingling sensations
- NO meningiomas (distinguishes from SMARCB1)
- Bilateral vestibular schwannomas are an EXCLUSION criterion
- Typical onset ages 20–40
The connection to Noonan syndrome adds clinical complexity — LZTR1 variants that cause Noonan are different in type and mechanism from those causing SWN-LZTR1, but a clinician seeing a patient with Noonan features and schwannomas should consider LZTR1 testing. No meningiomas in LZTR1 cases is a key distinguishing feature from SMARCB1.
Profile last updated 2026-08-19
SWI/SNF Related BAF Chromatin Remodeling Complex Subunit E1
A subunit of multiple SWI/SNF chromatin remodeling complexes — the same family as SMARCB1. Controls DNA packaging to regulate gene expression. Involved in DNA repair, replication, and cell growth and differentiation. Specific role within the complex not fully characterized.
- Multiple schwannomas
- Spinal and cranial meningiomas (particular association)
- Chronic pain
MedlinePlus does not yet list schwannomatosis as an associated condition for SMARCE1 — their entry only covers Coffin-Siris syndrome. The SWN-SMARCE1 connection is established by the 2022 Plotkin consensus and 2026 international update. The spinal/cranial meningioma association is a distinguishing clinical feature. Chromosome 17 location (vs. chromosome 22 for NF2, SMARCB1, LZTR1, DGCR8) indicates a distinct pathway entry point.
Profile last updated 2026-08-19
DGCR8 Microprocessor Complex Subunit
Part of the microprocessor complex with the enzyme Drosha. Processes primary microRNA (pri-miRNA) transcripts into precursor microRNA (pre-miRNA) — a fundamental step in the production of microRNAs that regulate gene expression throughout the body. This RNA-based mechanism is distinct from the chromatin remodeling biology of SMARCB1 and SMARCE1, and from the cell-adhesion biology of NF2/merlin.
- Multiple schwannomas
- Multinodular goiter (thyroid enlargement) — distinguishing feature not seen in other SWN subtypes
- Chronic pain
No MedlinePlus gene page exists yet for DGCR8. The SWN connection comes from Rivera et al. 2020 (JCI). The microRNA processing mechanism is biologically distinct from all other SWN genes — this may have implications for treatment targets. The thyroid involvement (multinodular goiter) is a clinical flag: SWN patients with thyroid disease may warrant DGCR8 testing even if standard SWN gene panels are negative.
Profile last updated 2026-08-19
NF2-SWN shares the schwannoma tumor type with all SWN subtypes, but it is a distinct clinical condition. Its hallmark is bilateral vestibular schwannomas — tumors on both hearing and balance nerves — along with meningiomas and ependymomas that do not appear in other SWN subtypes. NF2-SWN has an established research pipeline, clinical trials, and advocacy community, including the Children’s Tumor Foundation. We include NF2-SWN here for completeness and for the clinicians and researchers who work across the full schwannomatosis family.
Neurofibromin 2 (Moesin-Ezrin-Radixin Like)
Merlin regulates cell shape, growth, and attachment between cells. It controls several key signaling pathways that act as brakes on cell division. When merlin is absent or nonfunctional, Schwann cells — and other nervous system cells — multiply without restraint.
- Bilateral vestibular schwannomas (defining feature of NF2-SWN)
- Meningiomas
- Ependymomas
- Hearing loss and tinnitus
- Balance problems
- Facial weakness or paralysis
- Vision changes
- Cataracts (often childhood onset)
- Numbness or weakness in arms/legs
- Symptoms typically begin in adolescence or early twenties
The 2022 Plotkin et al. international consensus renamed NF2-related disease from "Neurofibromatosis Type 2" to NF2-SWN, placing it within the schwannomatosis family. The bilateral vestibular schwannoma presentation distinguishes NF2-SWN from all other SWN subtypes — it is both the hallmark of NF2-SWN and an exclusion criterion for LZTR1- and SMARCB1-related SWN. Literature using "NF2" as a disease name (not gene name) refers to what is now called NF2-SWN.
Profile last updated 2026-08-19
At a Glance
How the Subtypes Differ
NF2-SWN sits in a different clinical world than SMARCB1-, LZTR1-, SMARCE1-, and DGCR8-related schwannomatosis. They share a tumor type. Almost everything else diverges. NOS and NEC are included as classification states — NOS means genetic testing was not done; NEC means comprehensive testing was negative.
| Feature | NF2-SWN | SMARCB1-SWN | LZTR1-SWN | NOS / NEC | SMARCE1 / DGCR8 |
|---|---|---|---|---|---|
| Basics | |||||
| Gene / Chromosome | NF2 / Chr 22q12 | SMARCB1 / Chr 22q11 | LZTR1 / Chr 22q11 | Unknown | SMARCE1 (Chr 17) / DGCR8 (Chr 22q11) |
| Inheritance | AD | AD | AD or ARUnique among SWN genes | — | AD |
| Standard panel coverage | Yes | Yes | Yes | N/A | Not on standard panels |
| Dx requires genetic testing | No — clinical criteria sufficient | Yes | Yes | NOS: not doneNEC: done & negative | Yes |
| Tumors | |||||
| Bilateral vestibular schwannomas | Defining feature | Excluded | Typically excluded | Excluded | Not established |
| Spinal & peripheral schwannomas | Present | Hallmark | Hallmark | Hallmark | Present |
| Meningiomas | Very common45–58% of cases | PresentSpinal > intracranial | None documented | Possible | Spinal & cranialSMARCE1-specific |
| Ependymomas | Common33–53% of cases | Rare | Rare | Rare | Not established |
| Symptoms | |||||
| Dominant symptom | Hearing loss, tinnitus, balance problems | Chronic pain | Chronic pain | Chronic pain | Chronic pain |
| Pain as primary feature | No | Yes | Yes | Yes | Yes |
| Hearing loss | Yes — hallmark | Only if VS present | Only if VS present | Only if VS present | Not established |
| Eye findings | Cataracts, retinal hamartoma, epiretinal membrane | None | None | None documented | None documented |
| Typical onset | Teens–20s | 20s–40s | 20s–40s | Variable | Not established |
| Clinical Care | |||||
| Malignancy risk | Low | Low–moderateRhabdoid tumor risk in families; SMARCB1 is a tumor suppressor | Low | Unknown | Not established |
| Radiation avoidance | Standard caution | CriticalIncreases malignant transformation risk | Standard caution | Unknown | Not established |
| Annual audiology needed | Yes | Only if VS risk | Only if VS risk | Only if VS risk | Not established |
Sources: Plotkin SR et al., Genetics in Medicine, 2022; GeneReviews: NF2-Related Schwannomatosis (updated 2025); GeneReviews: LZTR1- and SMARCB1-Related Schwannomatosis (updated Dec 2025); Evans DG et al., ERN GENTURIS Clinical Practice Guidelines, 2022.
Differential Diagnosis
Clinical Presentation — NF2-SWN vs. SWN
Schwannomatosis presents very differently depending on subtype. Non-NF2 SWN (SMARCB1, LZTR1, NEC, NOS) is defined by severe chronic pain and peripheral or spinal schwannomas. NF2-SWN is defined by bilateral vestibular schwannomas and their consequences — hearing loss, balance problems, meningiomas, and ependymomas. Both involve schwannomas. The clinical picture is distinct enough that the two should never be grouped under a single treatment or surveillance protocol.
| Symptom / Sign | NF2-SWN | SWN — SMARCB1 / LZTR1 / NEC / NOS | Suggestive Tumor(s) |
|---|---|---|---|
| Hearing Loss (Bilateral) | Very Common | Rare / Uncommon | Vestibular Schwannomas |
| Tinnitus | Very Common | Rare | Vestibular Schwannomas |
| Balance Problems / Vertigo | Very Common | Rare | Vestibular Schwannomas |
| Facial Numbness or Paralysis | Common (cranial nerves) | Rare | Cranial Schwannomas (Trigeminal / Facial) |
| Vision Issues / Cataracts | Common | Rare / Uncommon | Associated Cataracts |
| Headaches | Common — meningiomas, cranial nerve compression | Common — central sensitization from chronic pain | Meningiomas (NF2-SWN); central sensitization (SWN) |
| Chronic Severe Pain | Common — cranial and spinal nerve compression | Hallmark — often severe, widespread, and multifocal | Peripheral Schwannomas, Spinal Schwannomas, Hybrid Tumors |
| Allodynia / Touch and Temperature Hypersensitivity | Occasional | Common — hallmark of central sensitization in SWN | Peripheral nerve sensitization; not tumor-site specific |
| Muscle Pain (Myalgia) | Occasional | Common — from involuntary nerve firing, periosteal pressure, and myofascial guarding | Peripheral nerve hyperexcitability; tumor proximity to bone or muscle |
| Peripheral Nerve Hyperexcitability (fasciculations, involuntary movements) | Rare | Documented — likely underreported; paroxysmal movements with preserved awareness | Nerve irritation from tumor proximity or chronic peripheral nerve disease |
| Post-Exertional Symptom Amplification | Uncommon | Common — delayed crash after minimal activity, partial recovery | Not tumor-site specific — chronic nervous system depletion |
| Sleep Disruption from Pain | Occasional | Common — pain at rest, spontaneous nerve firing, allodynia from contact | Not tumor-site specific — central sensitization |
| Numbness / Tingling / Paresthesia | Common | Very Common | Peripheral & Spinal Schwannomas |
| Weakness (Arms / Legs) | Common | Very Common | Spinal or Peripheral Schwannomas |
| Severe Spinal Pain | Common | Very Common | Spinal Schwannomas |
| Pain Before Tumor Visible on Imaging | Less Common | Common — pain can precede detectable tumor by months to years | Small tumors or tumors on unimaged nerve branches; peripheral sensitization |
| Multiple Tumors (no skin involvement) | Common | Common | Peripheral, Spinal Schwannomas, Hybrid Tumors |
| Hybrid Neurofibroma-Schwannoma | Rare (possible) | Strongly Suggestive of SWN-NEC | Hybrid Tumors |
| Cutaneous Neurofibromas (skin tumors) | Not Present | Not Present | N/A — Associated with NF1, not SWN |
Based on 2022 international consensus classification (Plotkin SR et al., Genet Med. 2022) and clinical reference prepared for the Order of the SWNs Foundation. For differential diagnosis guidance only — individual patients vary significantly.